4th Clinical Study
Evaluation of Efficacy and Safety of EstroG‑100® in Alleviating Menopausal Symptoms in Postmenopausal Women in India:
A Prospective, Single‑center, Single‑arm, Interventional Study
Study Dose:
514 mg/day
Study Duration:
12 weeks
No. of Participants:
58
Ref: J. Mid-life Health, 14: 285-290 (2023)
Summary
EstroG-100® significantly improved menopausal symptoms in Indian postmenopausal women following 12 weeks of supplementation. Treatment was associated with a significant enhancement in menopause-related quality of life and was well tolerated throughout the study period. These findings support EstroG-100® as a safe and effective non-hormonal intervention for the management of menopausal symptoms.
